acute myeloid leukemia acute myeloid leukemia
Conditions
Interventions
dose at initial:
Etoposide 50 mg/m2 + 6MP 60 mg/m2+ prednisolone 40mg/m2 PO OD 21 days q 28 days * 4 cycles
Evaluate response at 2 and 4 cycles
current dose:
Etoposide (25 mg) (5 days) BSA (1.0-
1.49) 1X2 BSA (1.5-
1.8) 1x3
6MP (50 mg) (2 wk) BSA (1.0-
1.49) 1X1 BSA (1.5-
1.8) 1x1
prednisolone (5 mg) (2wk) BSA (1.0-
1.49) 2X1 BSA (1.5-
1.8) 2x2,Hydroxyurea to keep the white blood cell less than 10,
000 cell/μL
Experimental Drug,Active Comparator Drug
metronomic,hydroxyurea
Sponsors
medicine department, Udonthani Hospital
Udonthani hospital
Eligibility
Sex/Gender
All
Age
55 Years to 105 Years
Inclusion criteria
Inclusion criteria: 1. The patients who diagnosed acute myeloid leukemia 2. Performance status 0-3 or 4 due to acute leukemia, not underlying disease 3. Age 55 years or older 4. Patient who refused intravenous chemotherapy 5. Informed patient
Exclusion criteria
Exclusion criteria: 1. Patient who can not come to follow up until end of the study 2. Patients with one of the following conditions (screening from medical documents) Congestive heart failure Decompensated cirrhosis Chronic kidney disease stage 3-4 COPD, mod-severe AIDS
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival rate death day | — |
Secondary
| Measure | Time frame |
|---|---|
| grade 3-4 toxicity and adverse events at visit case record form | — |
Countries
Thailand
Contacts
Public ContactSaranya Pongudom
medicine department, Udonthani hospital
Outcome results
None listed